Cas:9013-18-7 Acyl-coenzyme A synthetase manufacturer & supplier

Chemical Name:Acyl-coenzyme A synthetase

CAS.NO:9013-18-7

Synonyms:Fatty acid CoA ligase;Acetamide, N-[4-[[[(1Z)-3-[[[4-(acetylamino)phenyl]sulfonyl]amino]-4-oxo-1(4H)-naphthalenylidene]amino]sulfonyl]phenyl]-;Acyl-CoA ligase;N,N’-[(4-Oxo-3-naphthalenyl-1-ylidene)bis(sulfamoyl-4,1-phenylene)]diacetamide;Fatty acyl CoA synthetase;Hexanoyl-CoA synthetase;Fatty acid thiokinase (long chain);Acyl-CoA synthase;3-Hydroxyacyl-CoA synthase;Acyl-coenzyme A ligase;Fatty acid thiokinase;Acyl coenzyme A synthetase;Hexanoyl coenzyme A synthetase;Fatty acyl-coenzyme A synthetase;Fatty acyl-CoA ligase;Acyl CoA synthetase;E.C. 6.2.1.3

Molecular Formula:C₂₆H₂₂N₄O₇S₂

Molecular Weight:N/A

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like Fatty acid CoA ligase chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,E.C. 6.2.1.3 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Acyl CoA synthetase Use and application,Acetamide, N-[4-[[[(1Z)-3-[[[4-(acetylamino)phenyl]sulfonyl]amino]-4-oxo-1(4H)-naphthalenylidene]amino]sulfonyl]phenyl]- technical grade,usp/ep/jp grade.

Related News: As part of the deal, CROS NT CEO Paolo Morelli becomes Alira’s executive vice president of biometrics. Acyl-coenzyme A synthetase manufacturer As part of the deal, CROS NT CEO Paolo Morelli becomes Alira’s executive vice president of biometrics. Acyl-coenzyme A synthetase supplier As part of the deal, CROS NT CEO Paolo Morelli becomes Alira’s executive vice president of biometrics. Acyl-coenzyme A synthetase vendor Taking Teva as an example, it has 2 large R & D centers and 3 professional R & D centers in 5 countries, which effectively supports the development of Teva’s generic pharmaceutical sector. Acyl-coenzyme A synthetase factory The researchers found that compared with those with cancer, the prevalence of FT was higher among those with ASCVD (54 versus 41 percent). In adjusted analyses, when studying individual components of FT, those with ASCVD had increased odds of any difficulty paying medical bills, inability to pay bills, cost-related medication nonadherence, food insecurity, and foregone/delayed care due to cost (odds ratios, 1.22, 1.25, 1.28, 1.39, and 1.17, respectively).